刚刚滑 FB, 发现满多人在疯传
https://www.nature.com/articles/s41591-021-01377-8
大意就是中和抗体效价跟保护力正相关 赞赞 (Published: 17 May 2021)
美国 FDA 认为目前不能当保护力参考 (Date Issued: May 19, 2021)
results from currently authorized SARS-CoV-2 antibody tests should not be
used to evaluate a person's level of immunity or protection from COVID-19 at
any time, and especially after the person received a COVID-19 vaccination.
https://reurl.cc/7rpx3y
嘛，WHO 也还在争议并研究这点,
也有其他研究者尝试归纳其他变因 (Published: 09 June 2021)
https://www.nature.com/articles/s41586-021-03681-2
抗体可能不是决定保护力的单一因素, 像 T cells (May 27, 2021)
https://reurl.cc/LbMGea
不过中和抗体也并非真的不可取, 美国 FDA 有讨论扩大让低龄施打 (June 10, 2021)
(前提: 成人有效, 临床反应可能有差兼不适合对小屁孩试验, 所以考虑用非劣试验)
neutralizing antibodies can serve as a biomarker to infer COVID-19 vaccine
effectiveness in pediatric populations via immunobridging. Because no
specific neutralizing antibody titer has yet been established to predict
protection, rigorous immunobridging studies would compare the range of
neutralizing antibody responses in adult vs. pediatric populations by
evaluating both seroresponse rates...
https://www.fda.gov/media/149935/download
当全球正在实验辩证那些指标可以做为保护力参考时
独步世界的台湾 FDA 率先发难 (发布日期：2021-06-10)
研商以免疫桥接(immuno-bridging)方式，采用免疫原性(中和抗体)作为替代疗效指标，
衡量国产疫苗诱发产生的免疫原性结果是否与国人接种国外已核准EUA的疫苗相当，
作为支持国产疫苗疗效的佐证。
https://www.fda.gov.tw/TC/newsContent.aspx?cid=4&id=t600385
Google 一下不少医疗专区也超挺这个政策
这是否再次让全世界看到台湾优秀的超前部署了?